Achieve Life Sciences, Inc. (ACHV)
Technology · NasdaqCM
Fundamentals
Valuation and ratings
Achieve Life Sciences, Inc. trades at USD6.24. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
ACHV passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$3.17M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$3.00M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$1.73M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$111.0K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$82.2K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own ACHV?
5 of the institutions we track reported a position in ACHV in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for ACHV, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.